A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
-
![]()
News Guy Sauvageau Honored by the Stem Cell Network
Professor Guy Sauvageau, director of the Molecular Genetics of Stem Cells Research Unit, has been awarded the Stem Cell Network’s Trailblazer Award. This award recognizes individuals who have overcome major challenges in the field of regenerative medicine and developed solutions that advance care, policy, commercialization, or innovation within a system.
-
![]()
News Guy Sauvageau Named Knight of the Ordre de Montréal
On May 8, Professor Guy Sauvageau, Director of IRIC’s Molecular Genetics of Stem Cells Research Unit, will be presented with the insignia of the Ordre de Montréal as a Knight.
-
![]()
News RIMap-RISC: A New Interface to Study RNA Biology
The team led by François Major, director of IRIC’s RNA Engineering Research Unit, has developed the new RIMap-RISC database, which integrates the molecular structure of microRNAs and messenger RNAs to systematically model their interactions. Led by PhD student Simon Chasles, this work is the subject of a publication in Genome Biology.
-
![]()
News Marc Therrien’s team wins the 2025 Discovery of the Year Award - Québec Science
The team led by Marc Therrien, Principal Investigator and Chief Executive Officer at IRIC, has won Québec Science magazine’s 2025 Discovery of the Year award for its work on the BRAF protein and its role in the spread of cancer cells. The winner was chosen by the public, with more than 2,000 people participating in the vote.
-
![]()
News In Search of New Antibiotics to Counter Antibiotic Resistance
IRIC’s Drug Discovery Unit (DDU) is part of the project “Designing Antibiotics Targeting Klebsiella Using Artificial Intelligence,” which has received US$3.8 million (approximately CA$5.3 million) from the Gates Foundation.
-
![]()
News Meet Simon-Pierre Gravel, new Principal Investigator at IRIC!
IRIC is proud to announce the arrival of Simon-Pierre Gravel as the new Principal Investigator in the Cancer metabolism and signaling Unit. Simon-Pierre Gravel has kindly agreed to answer a few questions
Latest publications
See all publications-
May 15, 2026 -
May 7, 2026 Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long-chain fatty acid accumulation after myocardial ischemia-reperfusion in mice.
Gauvin J, Radmannia N, Huynh DN, Ménard L, Daneault C, Veilleux M, Ahsanullah A, Carpentier AC, Lubell WD, Ruiz M, Ong H, Marleau S, Gravel S
FEBS Open Bio 2026-05-07 ; - See all publications